Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human LCAT Anticorps:
anti-Mouse (Murine) LCAT Anticorps:
anti-Rat (Rattus) LCAT Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal LCAT Primary Antibody pour ELISA, WB - ABIN152886
Furbee, Francone, Parks: In vivo contribution of LCAT to apolipoprotein B lipoprotein cholesteryl esters in LDL receptor and apolipoprotein E knockout mice. dans Journal of lipid research 2002
Show all 7 Pubmed References
Polyclonal LCAT Primary Antibody pour WB - ABIN540393
Lee, Badeau, Mulya, Boudyguina, Gebre, Smith, Parks: Functional LCAT deficiency in human apolipoprotein A-I transgenic, SR-BI knockout mice. dans Journal of lipid research 2007
Show all 5 Pubmed References
Human Polyclonal LCAT Primary Antibody pour ICC, IF - ABIN438375
Mulya, Lee, Gebre, Boudyguina, Chung, Smith, Colvin, Jiang, Parks: Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL. dans Journal of lipid research 2008
Show all 3 Pubmed References
Cow (Bovine) Polyclonal LCAT Primary Antibody pour WB - ABIN2776941
Calabresi, Pisciotta, Costantin, Frigerio, Eberini, Alessandrini, Arca, Bon, Boscutti, Busnach, Frascà, Gesualdo, Gigante, Lupattelli, Montali, Pizzolitto, Rabbone, Rolleri, Ruotolo, Sampietro, Sessa, Vaudo, Cantafora, Veglia, Calandra, Bertolini, Frances: The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. dans Arteriosclerosis, thrombosis, and vascular biology 2005
Show all 2 Pubmed References
the crystal structure of human LCAT in complex with a potent piperidinylpyrazolopyridine activator and an acyl intermediate-like inhibitor, revealing LCAT in an active conformation, is reported.
Plasma LCAT activity was higher in patients with NAFLD.
results demonstrated increased CETP and decreased LCAT and PON-1 activities in colorectal cancer (CRC)patients. In preliminary analysis CETP mass was identified as potential significant predictor of CRC development, suggesting that alterations in HDL-C levels, alongside with changes in HDL structure might have a role in carcinogenesis.
It has been found a significant association between LCAT serum activity and risk of diabetes mellitus in men but not in women.
Single Nucleotide Polymorphism in LCAT gene is associated with dyslipidemia.
data suggests a model wherein the active site of LCAT is shielded from soluble substrates by a dynamic lid until it interacts with HDL to allow transesterification to proceed
Increased LCAT activity may be associated with increased formation of triglyceride rich lipoproteins, leading to a reduction in LDL particle size and atherosclerosis.
Mapping the naturally occurring mutations onto the structure provides insight into how they may affect LCAT enzymatic activity.
Report slightly reduction in LCAT that would probably reflect a delay in reverse cholesterol transport occurring in MetS.
rs5923 polymorphism is not associated with low high-density lipoprotein cholesterol(HDL-C)levels in Iranian population
increased cholesterol esterification by LCAT is atheroprotective
The data indicate that this novel apoA-I missense is associated with markedly decreased levels of HDL cholesterol and very large alpha-1 HDL, as well as decreased serum cellular cholesterol efflux and LCAT activity
A robust all-atom model for LCAT generated by homology modeling
genetic polymorphism is associated with coronary artery disease in Egyptians
This study investigated how the natural LCAT[T147I] and LCAT[P274S] mutations affect the pathway of biogenesis of high-density lipoproteins.
A synonymous H287H mutation in the coding region of exon 6 of the lecithin cholesterol acyltransferase gene was observed in an individual with HDLC levels of 75 mg/dl.
Cosyntropin testing in an unselected subgroup of 8 ABCA1 mutation carriers and 3 LCAT mutation carriers did not reveal differences between carriers and controls.
The enzyme lecithin-cholesterol acyltransferase esterifies cerebrosterol and limits its toxic effect on cultured neurons.
Activity of LCAT in HDL was increased in type 2 diabetes following increased fruit and vegetable intake.
Results show that recombinant lecithin:cholesterol acyltransferase rhLCAt efficiently reduces the amount of unesterified cholesterol and promotes the production of plasma cholesteryl esters in LCAT deficient plasma.
Taken together, these results suggest that apoE-containing discoidal HDLs do not require LCAT-dependent maturation to mediate efficient Abeta clearance
Gene transfer of WT LCAT in LCAT(-/-) mice increased 11.8-fold the plasma cholesterol, whereas the LCAT[T147I] and LCAT[P274S] mutants caused a 5.2- and 2.9-fold increase, respectively.
DYRK1A overexpression decreases plasma lecithin:cholesterol acyltransferase activity and apolipoprotein A-I levels.
adrenal glucocorticoid function in LCAT knockout (KO) mice
a novel function of apoA-IV in the biogenesis of discrete HDL-A-IV particles with the participation of ABCA1 and LCAT
Studies suggest that absence of lecithin cholesterol acyltransferase (LCAT) may protect against insulin resistance, diabetes and obesity.
Data show that LCAT activity was significantly higher in long chain base biosynthesis protein 2 (Sptlc2)+/- and sphingomyelin synthase 2 (Sms2)-/- mice, but markedly lower in ApoE-/- and Ldlr-/- mice.
Lecithin:cholesterol acyltransferase deficiency protects against cholesterol-induced hepatic endoplasmic reticulum stress in mice.
LCAT deficiency confers gender-specific protection against diet-induced obesity and insulin resistance at least in part through regulation in UPR, white adipose tissue adipogenesis, and brown adipocyte partitioning
Oxidative stress is markedly elevated in lecithin:cholesterol acyltransferase-deficient mice and is paradoxically reversed in the apolipoprotein E knockout background in association with a reduction in atherosclerosis
LCAT contributes significantly to the cholesteryl ester (CE) fatty acid pool of apoB lipoprotein and is the only source of plasma long chain polyunsaturated CE in LDL receptor and apoE knockout mice.
hypertriglyceridemia and the improved fasting glucose phenotype seen in the lecithin-cholesterol acyltransferase and ldl receptor double knockout mice are in part attributable to up-regulation of hepatic sterol regulatory element binding factor-1c gene
LCAT has a role in regulating plasma HDL cholesterol levels and biliary cholesterol excretion
apoE is a more significant activator of LCAT than apoA-I on mouse apoB lipoproteins
ACAT2 provides core CE of newly secreted VLDL, whereas LCAT adds CE during LDL particle formation
In LCAT deficient mice, alterations in hepatic expression of the gene for fads2, soat2, and dgat2, results in changes in total hepatic and cholesterol ester-associated polyunsaturated fatty acids.
LCAT deficiency induces complex alterations in hepatic signal transduction cascades.
These data show that brain LCAT esterifies cholesterol on glial-derived apoE-lipoproteins, and influences CSF apoE and apoA-I levels.
LCAT overexpression does not promote an increased rate of macrophage reverse cholesterol transport.
LCAT cholesterol esterification is associated with the increase of ApoE/ApoA-I ratio during atherosclerosis progression in rabbit.
The 1,434 bp mRNA sequence of porcine LCAT including the full coding region and encoding a protein of 472 amino acids, was obtained.
This gene encodes the extracellular cholesterol esterifying enzyme, lecithin-cholesterol acyltransferase. The esterification of cholesterol is required for cholesterol transport. Mutations in this gene have been found to cause fish-eye disease as well as LCAT deficiency.
, phospholipid-cholesterol acyltransferase
, lecithin-cholesterol acyltransferase Lcat
, lecithin-cholesterol acyltransferase
, lecithin cholesterol acyltransferase
, Lecithin-cholesterol acyltransferase